Zoetis Inc. (ZTS) Share buybacks
- Total buybacks · last 12 months (USD): Value $3.64B; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $3.64B | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 3.64B USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $3.64B | (m) | (m) |
| 2026-03-31 | $3.40B | (m) | (m) |
| 2025-12-31 | $3.23B | (m) | (m) |
| 2025-12-18 | (m) | (m) | (m) |
| 2025-09-30 | $1.73B | (m) | (m) |
| 2025-06-30 | $1.77B | (m) | (m) |
| 2025-03-31 | $1.96B | (m) | (m) |
| 2024-12-31 | $1.86B | (m) | (m) |
| 2024-09-30 | $1.54B | (m) | (m) |
| 2024-06-30 | $1.36B | (m) | (m) |
| 2024-03-31 | $1.15B | (m) | (m) |
| 2023-12-31 | $1.09B | (m) | (m) |
| 2023-09-30 | $1.26B | (m) | (m) |
| 2023-06-30 | $1.39B | (m) | (m) |
| 2023-03-31 | $1.52B | (m) | (m) |
| 2022-12-31 | $1.59B | (m) | (m) |
| 2022-09-30 | $1.39B | (m) | (m) |
| 2022-06-30 | $1.21B | (m) | (m) |
| 2022-03-31 | $923.00M | (m) | (m) |
| 2021-12-31 | $743.00M | (m) | (m) |
| 2021-09-30 | $545.00M | (m) | (m) |
| 2021-06-30 | $347.00M | (m) | (m) |
| 2021-03-31 | $181.00M | (m) | (m) |
| 2020-12-31 | $250.00M | (m) | (m) |
| 2020-09-30 | $426.00M | (m) | (m) |
| 2020-06-30 | $576.00M | (m) | (m) |
| 2020-03-31 | $726.00M | (m) | (m) |
| 2019-12-31 | $626.00M | (m) | (m) |
| 2019-09-30 | $600.00M | (m) | (m) |
| 2019-06-30 | $593.00M | (m) | (m) |
| 2019-03-31 | $658.00M | (m) | (m) |
| 2018-12-31 | $698.00M | (m) | (m) |
| 2018-09-30 | $673.00M | (m) | (m) |
| 2018-06-30 | $655.00M | (m) | (m) |
| 2018-03-31 | $565.00M | (m) | (m) |
| 2017-12-31 | $500.00M | (m) | (m) |
| 2017-10-01 | $450.00M | (m) | (m) |
| 2017-07-02 | $399.00M | (m) | (m) |
| 2017-04-02 | $349.00M | (m) | (m) |
| 2016-12-31 | $300.00M | (m) | (m) |
| 2016-10-02 | $278.00M | (m) | (m) |
| 2016-07-03 | $254.00M | (m) | (m) |
| 2016-04-03 | $231.00M | (m) | (m) |
| 2015-12-31 | $203.00M | (m) | (m) |
| 2015-09-27 | (m) | (m) | (m) |
| 2015-06-28 | (m) | (m) | (m) |
| 2015-03-29 | (m) | (m) | (m) |
| 2014-12-31 | $0.00 | (m) | (m) |
| 2014-09-28 | (m) | (m) | (m) |
| 2014-06-29 | (m) | (m) | (m) |
| 2014-03-30 | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |